The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology
Mike A Laffan, Will Lester, James S O'Donnell, Andrew Will, Robert Campbell Tait, Anne Goodeve, Carolyn M Millar, David M Keeling, Mike A Laffan, Will Lester, James S O'Donnell, Andrew Will, Robert Campbell Tait, Anne Goodeve, Carolyn M Millar, David M Keeling
No abstract availableKeywords: United Kingdom Haemophilia Centre Doctors Organization; diagnosis; guideline; management; von Willebrand.
Conflict of interest statement
Conflict-of-Interest Disclosure: ML has received speaker fees from Bayer, Octapharma and Pfizer, advisory board fees from CSL-Behring, Pfizer, Bayer and Grifols and research support from Bayer and CSL Behring. WL has received speaker fees and travel support from CSL and advisory board fees from Octapharma. JSOD has served on the speakers bureau for Baxter, Bayer, Novo Nordisk, Leo Pharma and Octapharma; served on the advisory boards of Baxter, Bayer, Octapharma and Pfizer and received research grant funding awards from Baxter, Bayer and Novo Nordisk. AW has no declarations of interest relating to this guideline. AG has received speaker fees from Octapharma and VWF mutation database support from CSL Behring. CMM has received research grant funding award and speaker fees from CSL Behring and Baxter and served on advisory boards for CSL and NovoNordisk. DMK has served on advisory boards for Baxter, CSL, Bayer, Pfizer and NovoNordisk. RCT has received speaker and/or consultancy fees from Baxter, Pfizer & Bayer
Figures
Source: PubMed